Cumberland Pharmaceuticals (CPIX) vs. The Competition Financial Review

Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Cumberland Pharmaceuticals to related businesses based on the strength of its profitability, institutional ownership, risk, earnings, analyst recommendations, valuation and dividends.

Institutional & Insider Ownership

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cumberland Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cumberland Pharmaceuticals 1 0 0 0 1.00
Cumberland Pharmaceuticals Competitors 7820 13784 25797 1036 2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.64%. Given Cumberland Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Cumberland Pharmaceuticals has less favorable growth aspects than its competitors.

Risk & Volatility

Cumberland Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals’ competitors have a beta of -0.05, indicating that their average stock price is 105% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cumberland Pharmaceuticals and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cumberland Pharmaceuticals $44.52 million -$2.84 million 1.39
Cumberland Pharmaceuticals Competitors $3.54 billion $3.17 billion 553.76

Cumberland Pharmaceuticals’ competitors have higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Cumberland Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cumberland Pharmaceuticals 274.38% -31.40% -9.38%
Cumberland Pharmaceuticals Competitors -2,393.19% -220.45% -16.12%

Summary

Cumberland Pharmaceuticals competitors beat Cumberland Pharmaceuticals on 8 of the 13 factors compared.

Cumberland Pharmaceuticals Company Profile

(Get Free Report)

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee. Founded in 1999, the company develops, acquires and commercializes branded prescription medicines, with a focus on products used in hospital and other acute-care settings as well as treatments for chronic conditions. Its marketed products include Acetadote, an intravenous treatment for acetaminophen overdose; Caldolor, an intravenous ibuprofen product used to treat pain and fever; and Kristalose, a prescription treatment for constipation.

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.